Patents by Inventor Herbert L. Heyneker

Herbert L. Heyneker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5254463
    Abstract: Microbial expression of an exogenous polypeptide may be inefficient if the messenger RNA has secondary structure (due to complementarity of spaced regions of the molecule) which impedes interaction with a ribosome. The occurrence of such structure can be predicted. The degeneracy of the genetic code gives freedom to alter the nucleic acid composition of the CDNA to eliminate harmful secondary structure of the MRNA.For example, bovine growth hormone (BGH) is poorly expressed by E. coli transformed with a recombinant plasmid containing the natural BGH gene. The corresponding MRNA has complementary regions at 46-51 and 73-78. Therefore a plasmid PBGH 33-4 was constructed containing a BGH gene whose upstream portion was synthesized (making use of plasmid PHGH 207-1 which contains an efficiently expressible gene for the closely related human growth hormone) so as not to cause the troublesome complementarity. E. coli transformed therewith produced BGH with-a yield of better than 10.sup.5 copies per cell.
    Type: Grant
    Filed: September 12, 1990
    Date of Patent: October 19, 1993
    Assignee: Genentech, Inc.
    Inventors: Herman A. de Boer, Herbert L. Heyneker, Peter H. Seeburg
  • Patent number: 5219569
    Abstract: Novel single-chain protease resistant urokinase derivatives are provided. In particular, derivatives are provided wherein the Lys.sub.135 Lys.sub.136 and Arg.sub.156 to Lys.sub.158 sites are rendered less susceptible to proteolytic cleavage are provided by occluding the sites or by covalently modifying them. Preferred covalent modifications are amino acid sequence variants at the sites where proteolysis of urokinase occurs. These are optimally produced by synthesis of single-chain urokinase mutants in recombinant cell culture. The novel urokinase derivatives herein offer the advantage of avoiding the generation of substantial two-chain urokinase, either in vivo or during recombinant cell culture. However, the derivatives continue function to activate plasminogen in initiating blood clot lysis.
    Type: Grant
    Filed: August 16, 1985
    Date of Patent: June 15, 1993
    Assignee: Genentech, Inc.
    Inventors: Michael Blaber, Herbert L. Heyneker, Gordon A. Vehar
  • Patent number: 5147643
    Abstract: Biologically active mutant tissue plasminogen activators are disclosed wherein site directed mutagenesis, for example, of a two-chain activation site renders the mutants resistant to conversion to the two-chain form.
    Type: Grant
    Filed: August 5, 1991
    Date of Patent: September 15, 1992
    Assignee: Genentech, Inc.
    Inventor: Herbert L. Heyneker
  • Patent number: 5112755
    Abstract: Human urokinase is produced using recombinant DNA techniques. The invention disclosed thus enables the production of urokinase free of contaminants with which it is ordinarily associated in its native cellular environment. Methods, expression vehicles and various host cells useful in its production are also disclosed.
    Type: Grant
    Filed: July 19, 1988
    Date of Patent: May 12, 1992
    Assignee: Genentech, Inc.
    Inventors: Herbert L. Heyneker, William E. Holmes, Gordon A. Vehar
  • Patent number: 5073494
    Abstract: Biologically active mutant tissue plasminogen activators are disclosed wherein site directed mutagenesis, for example, of a two-chain activation site renders said mutants resistant to conversion to the two-chain form.
    Type: Grant
    Filed: May 11, 1990
    Date of Patent: December 17, 1991
    Assignee: Genentech, Inc.
    Inventors: Herbert L. Heyneker, Gordon A. Vehar
  • Patent number: 4963495
    Abstract: Direct linkage of DNA encoding prokaryotic signals such as E. coli enterotoxin with DNA encoding mature eukaryotic proteins followed by transformation and culture of bacterial hosts characterized by a periplasmic space, yields substantial amounts of periplasmic mature protein.
    Type: Grant
    Filed: October 5, 1984
    Date of Patent: October 16, 1990
    Assignee: Genentech, Inc.
    Inventors: Chung N. Chang, Gregory L. Gray, Herbert L. Heyneker, Michael W. Rey
  • Patent number: 4898830
    Abstract: Described are methods and means for the construction and microbial expression of quasi-synthetic genes arising from the combination of organic synthesis and enzymatic reverse transcription from messenger RNA sequences incomplete from the standpoint of the desired protein product. Preferred products of expression lack bio-inactivating leader sequences common in eukaryotic expression products but problematic with regard to microbial cleavage to yield bioactive material. Illustrative is a preferred embodiment in which a gene coding for human growth hormone (useful in, e.g., treatment of hypopituitary dwarfism) is constructed and expressed.
    Type: Grant
    Filed: April 13, 1987
    Date of Patent: February 6, 1990
    Assignee: Genentech, Inc.
    Inventors: David V. Goeddel, Herbert L. Heyneker
  • Patent number: 4859600
    Abstract: The production of mature hGH in E coli and Pseudomonas strains transformed by a plasmid which encodes pre hGH (comprising the signal polypeptide and the hormone itself) is described. These prokaryotes process the pre-hGH to cleave the signal sequence and, thereby, produce mature hGH.
    Type: Grant
    Filed: April 26, 1988
    Date of Patent: August 22, 1989
    Assignee: Genentech, Inc.
    Inventors: Gregory L. Gray, Herbert L. Heyneker
  • Patent number: 4816567
    Abstract: Altered and native immunoglobulins, including constant-variable region chimeras, are prepared in recombinant cell culture. The immunoglobulins contain variable regions which are immunologically capable of binding predetermined antigens. Methods are provided for refolding directly expressed immunoglobulins into immunologically active form.
    Type: Grant
    Filed: April 8, 1983
    Date of Patent: March 28, 1989
    Assignee: Genentech, Inc.
    Inventors: Shmuel Cabilly, Herbert L. Heyneker, William E. Holmes, Arthur D. Riggs, Ronald B. Wetzel
  • Patent number: 4755465
    Abstract: The production of mature hGH In E. coli and Pseudomonas strains transformed by a plasmid which encodes pre hGH (comprising the signal polypeptide and the hormone itself) is described. These prokaryotes process the pre-hGH to cleave the signal sequence and, thereby, produce mature hGH.
    Type: Grant
    Filed: April 25, 1983
    Date of Patent: July 5, 1988
    Assignee: Genentech, Inc.
    Inventors: Gregory L. Gray, Herbert L. Heyneker
  • Patent number: 4663283
    Abstract: A method of altering double stranded DNA comprising converting double stranded DNA to single stranded DNA in a region surrounding a selected cleavage site, hybridizing a complimentary primer to the single stranded region formed in the previous step, and restoring enzymatically the second strand which had been eliminated.
    Type: Grant
    Filed: October 20, 1983
    Date of Patent: May 5, 1987
    Assignee: Genentech, Inc.
    Inventors: Dennis G. Kleid, Daniel G. Yansura, Herbert L. Heyneker, Giuseppe F. Miozzari
  • Patent number: 4658021
    Abstract: Described are methods and means for the construction and microbial expression of quasi-synthetic genes arising from the combination of organic synthesis and enzymatic reverse transcription from messenger RNA sequences incomplete from the standpoint of the desired protein product. Preferred products of expression lack bio-inactivating leader sequences common in eukaryotic expression products but problematic with regard to microbial cleavage to yield bioactive material. Illustrative is a preferred embodiment in which a gene coding for human growth hormone (useful in, e.g., treatment of hypopituitary dwarfism) is constructed and expressed.
    Type: Grant
    Filed: September 25, 1984
    Date of Patent: April 14, 1987
    Assignee: Genentech, Inc.
    Inventors: David V. Goeddel, Herbert L. Heyneker
  • Patent number: 4634677
    Abstract: Described are methods and means for the construction and microbial expression of quasi-synthetic genes arising from the combination of organic synthesis and enzymatic reverse transcription from messenger RNA sequences incomplete from the standpoint of the desired protein product. Preferred products of expression lack bio-inactivating leader sequences common in eukaryotic expression products but problematic with regard to microbial cleavage to yield bioactive material. Illustrative is a preferred embodiment in which a gene coding for human growth hormone (useful in, e.g., treatment of hypopituitary dwarfism) is constructed and expressed.
    Type: Grant
    Filed: August 26, 1981
    Date of Patent: January 6, 1987
    Assignee: Genentech, Inc.
    Inventors: David V. Goeddel, Herbert L. Heyneker
  • Patent number: 4604359
    Abstract: Described are methods and means for the construction and microbial expression of quasi-synthetic genes arising from the combination of organic synthesis and enzymatic reverse transcription from messenger RNA sequences incomplete from the standpoint of the desired protein product. Preferred products of expression lack bio-inactivating leader sequences common in eukaryotic expression products but problematic with regard to microbial cleavage to yield bioactive material. Illustrative is a preferred embodiment in which a gene coding for human growth hormone (useful in, e.g., treatment of hypopituitary dwarfism) is constructed and expressed.
    Type: Grant
    Filed: March 9, 1982
    Date of Patent: August 5, 1986
    Assignee: Genentech, Inc.
    Inventors: David V. Goeddel, Herbert L. Heyneker
  • Patent number: 4601980
    Abstract: Described are methods and means for the construction and microbial expression of quasi-synthetic genes arising from the combination of organic synthesis and enzymatic reverse transcription from messenger RNA sequences incomplete from the standpoint of the desired protein product. Preferred products of expression lack bio-inactivating leader sequences common in eukaryotic expression products but problematic with regard to microbial cleavage to yield bioactive material. Illustrative is a preferred embodiment in which a gene coding for human growth hormone (useful in, e.g., treatment of hypopituitary dwarfism) is constructed and expressed.
    Type: Grant
    Filed: March 9, 1982
    Date of Patent: July 22, 1986
    Assignee: Genentech Inc.
    Inventors: David V. Goeddel, Herbert L. Heyneker
  • Patent number: 4342832
    Abstract: Described are methods and means for the construction and microbial expression of quasi-synthetic genes arising from the combination of organic synthesis and enzymatic reverse transcription from messenger RNA sequences incomplete from the standpoint of the desired protein product. Preferred products of expression lack bio-inactivating leader sequences common in eukaryotic expression products but problematic with regard to microbial cleavage to yield bioactive material. Illustrative is a preferred embodiment in which a gene coding for human growth hormone (useful in, e.g., treatment of hypopituitary dwarfism) is constructed and expressed.
    Type: Grant
    Filed: July 5, 1979
    Date of Patent: August 3, 1982
    Assignee: Genentech, Inc.
    Inventors: David V. Goeddel, Herbert L. Heyneker